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ABSTRACT 
Host immunity influences the impact of radiotherapy (RT) in cancer but mechanistic connections 
remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase 
(IDO) systemic activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC). 
IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood 
serum were determined for stage III NSCLC patients at times before, during and after RT 
administration and then correlated to overall survival (OS), progression-free survival and disease 
progression rate in patients. We found the impact of RT on these serum IDO markers to be 
heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but 
restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels 
of kynurenine after RT were significantly associated with OS. When combined, favorable change 
and favorable baseline corresponded with very long-term OS (median OS was not reached after 
57 months median follow-up). Favorable change combined with unfavorable baseline still 
corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated 
immune status in NSCLC patients and that changes in this serum biomarker may be useful to 
predict outcomes and perhaps personalize RT dosage to improve survival. 
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INTRODUCTION 
Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer, which is the leading 
cause of cancer death in the United States (1). Approximately 64% of patients with NSCLC 
require radiotherapy (RT) at least once during their course of disease (2). Recently, it has been 
reported that radiation induced tumor killing can activate the immune system by generating 
tumor specific antigens and converting the tumor into an individualized in situ vaccine (3). 
Animal studies have demonstrated that a combination of hypo-fractionated RT with 
immunotherapy generated synergetic effects on local tumor control and even abscopal effects for 
tumor killing outside the treatment fields (3-5). The RT abscopal effect has been reported in a 
few clinical cases, including one melanoma case in the New England Journal of Medicine (4).  
Indoleamine 2, 3-dioxygenase (IDO) is an intercellular enzyme that converts the essential amino 
acid tryptophan into kynurenine through the IDO/kynurenine pathway (6). IDO depletes 
tryptophan in the tumor microenvironment and activates immune checkpoint via amino acid 
sensor general control nonderepressible 2 (GCN2) (7,8). Kynurenine, the direct metabolite of 
this pathway, and its further downstream metabolites, promotes potent immune suppression by 
enhancing Foxp3-regulatory T cell functions and attenuating responses of effector T cells and 
natural killer cells (9,10). Previous studies have validated IDO as a potent immune checkpoint in 
cancers and other chronic inflammatory diseases (11-13). Because tryptophan and kynurenine 
concentrations can be measured from patients’ serum, IDO activity can be monitored by 
computing kynurenine to tryptophan (K:T) ratio. Clinical studies have reported that IDO activity 
correlated with the number of tumor infiltrating lymphocytes in esophageal and colorectal 
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cancers (14,15), and elevated IDO activity correlated with poor clinical outcomes in several 
types of cancers (16-19), including lung cancer (20-22). These clinical data further support that 
IDO is an immune checkpoint that mediates anti-tumor immune activity. However, it is not clear 
how this IDO-mediated immune activity changes during or after RT in cancer patients, and 
whether these changes have any impact on tumor control or survival.  
In this study, we hypothesized that RT can alter the IDO-mediated anti-tumor immune activity 
which will impact on tumor progression or survival in patients with NSCLC. To test this 
hypothesis, we assessed IDO-mediated immune activity by quantifying the key molecules 
associated with the IDO checkpoint, including kynurenine and the K:T ratio (a commonly used 
surrogate for IDO activity), at pre-RT, 2-week (during-RT), 4-week (during-RT) and post-RT (3 
months after RT completion). We then performed survival analysis to correlate these parameters 
and their changes with progression free survival (PFS), overall survival (OS) and distant tumor 
progression.  
MATERIALS AND METHODS 
Patients and Treatment 
Patients with stage III inoperable/unresectable NSCLC enrolled institutional review board (IRB) 
approved prospective protocols were eligible. The protocols were conducted according to 
requirements of Belmont Report and U.S. Common Rules. All subjects signed informed written 
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consent before enrollment. All patients received conventionally fractionated daily RT, which was 
given using 3D conformal radiotherapy (3DCRT) as previously described (23,24). Details of 
these prospective trials were summarized in supplement Table S1. Equivalent dose at 2 Gy 
fraction (EQD2) were computed for those received other than 2 Gy daily doses, using alpha/beta 
of 10.  
Patients Follow-up and Samples/Clinical Data Collection 
Patients were examined weekly during the course of RT, followed up approximately every 3 
months during the first year, every 6 months during the second year and then annually thereafter. 
Clinical and follow-up data, including age, gender, smoking history, histology, clinical stage, 
tumor volume, Karnofsky performance score (KPS), EQD2 and chemotherapy, were recorded 
prospectively up to 2 years after completion of RT. Red top blood collection tubes without 
anticoagulants were used for serum. Blood samples of patients were collected at up to four time 
points of pre-RT, 2- and 4-week during-RT, and post-RT (generally first follow-up at 3 months 
after RT completion).  
Measurements of Serum Tryptophan and Kynurenine 
Serum tryptophan and kynurenine concentrations were measured using a high performance 
liquid chromatography system (Shimadzu LC20) as described before with minor modification 
(25,26). 25µl of serum samples were diluted with equal volumes of 30mM NaAc pH4.0 and 
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deproteinated with perchloric acid. Kynurenine was detected on an UV channel at 360nm and 
tryptophan was detected on a fluorescence channel at 285nm excitation and 365nm emission. 
Samples were analyzed using Lab SolutionTM software (Shimadzu). Samples were quantified 
with external standards and at least one quality control samples were randomly inserted into 
every plate for reference. For quality control purposes, double-blinding duplicate/triplicate 
testing verified the assay reproducibility to be over 95%.  
Statistical Analysis 
OS and PFS were the primary endpoints. OS was computed from RT start to the date of death of 
any cause. PFS was defined from start of RT to the date of any progression or death. Patients 
were censored at last follow-up if progression or death had not occurred. Kaplan-Meier log-rank 
test was applied to compare the survival difference between groups. Clinical variables with log-
rank P<0.05 under univariate analysis were selected as co-variants for adjustment in multivariate 
analysis. Multivariate Cox proportional hazards model was used to estimate hazard ratios (HR) 
with 95% confidence interval (95% CI). The IDO-checkpoint associated molecules from the 4 
time points were compared using repeated analysis of variance (ANOVA) (equivalent to paired t 
test for 2 groups). Considering 2 markers × 2 time points in survival analysis, Bonferroni 
correction for multiple testing was performed for statistical significance at a P<0.0125 (0.05/4) 
level. All statistical analyses were performed using IBM® SPSS Statistics 22.0 (IBM, Inc.). 
Scatter plot figures of IDO dynamic changes were generated using GraphPad Prism® (version 
5.01). 
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RESULTS 
Study Population and Overall Clinical Outcomes  
Of 182 patients enrolled, 110 patients staged III with quality samples available for IDO testing 
formed the primary study population. There were 103 Caucasian (94%) and 29 (26%) females. 
The median age was 66 years. All patients (100%) received definitive dose (≥ 60 Gy) of 3DCRT 
and 103 (94%) of whom underwent concurrent platinum-based chemotherapy. Table 1 details the 
patient demographic and clinical features. The median follow-up time was 56 months (95% CI, 
49-63 months). The median OS and PFS were 23 (95% CI, 17-29) and 11 (95% CI, 7-15) 
months, respectively. Univariate analysis showed that age (P=0.016), gender (P=0.040), tumor 
volume (P=0.010), KPS (P<0.001) and EQD2 (P=0.014) were significant for OS. Younger, 
female, smaller tumor volume, higher KPS and higher EQD2 had better OS. However, only 
tumor volume (P=0.041), KPS (P=0.010) and EQD2 (P=0.004) were significant for PFS (Table 
1). These clinical factors were thus selected as clinical co-variants for further multivariate 
analysis of IDO checkpoint associated parameters. 
Dynamics of Kynurenine and K:T Ratio at Different Time Points 
Serum kynurenine and K:T ratio changed heterogeneously through 4 time points from pre-RT, to 
2- and 4-week during-RT, and post-RT (Figure 1A-B). Mean kynurenine concentrations did not 
change significantly at 2-week of RT, but increased at 4-week during-RT, and increased further 
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post-RT. Kynurenine concentrations post-RT were significantly higher than that of other time 
points. The mean K:T ratio decreased from pre to 2-week and to 4-week during-RT, and 
increased sharply post-RT. The K:T ratio at the post-RT was significantly higher than that of pre- 
and during-RT time points. K:T ratio at 2-week was significantly lower than that of pre-RT 
under the paired t-test analysis (P=0.007).  
Baseline IDO Biomarkers and Outcome  
Kynurenine at pre-RT was not significantly correlated with OS (HR=1.03, 95%CI=0.73-1.45; 
P=0.887) or PFS (HR=0.99, 95%CI=0.71-1.37; P=0.927) (Table 2). K:T ratio at pre-RT 
correlated significantly with OS (HR, 2.36; 95% CI, 1.21-4.59; P=0.011) and PFS (HR, 1.77; 
95% CI, 1.02-3.05; P=0.042) (Figure 2A and 2B, Table 2) after adjusting for the clinical 
significant factors. However, only the P-value for OS remained significant after Bonferroni’s 
correction. High K:T ratio correlated significantly with poorer survival.  
 Post-RT IDO Biomarkers and Outcome 
None of the post-RT levels in kynurenine or K:T ratio was significant for OS or PFS. Among 
various RT-induced changes of these IDO checkpoint molecules, only change in kynurenine was 
significant. Using median as the cut-off, greater levels of post/pre kynurenine correlated 
significantly with worse OS (HR, 1.35, 95% CI, 1.09-1.68, P=0.006) and poorer PFS (HR, 1.31, 
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95% CI, 1.04-1.66, P=0.025). (Figure 3A and 3B, Table 2). However, only the P-value for OS 
remained significant after Bonferroni’s correction. 
Combined Effects of Baseline and Change of IDO Biomarker on OS, PFS and Metastasis 
To study the combined effects of baseline and change of IDO activities, patients were stratified 
into the following 4 groups according to the medians of pre-RT K:T ratio and post/pre 
kynurenine: 1) low pre-RT K:T ratio and low post/pre kynurenine (favorable baseline and 
favorable change); 2) high pre-RT K:T ratio and low post/pre kynurenine (unfavorable baseline 
and favorable change); 3) low pre-RT K:T ratio and high post/pre kynurenine (favorable baseline 
and unfavorable change); 4) high pre-RT K:T ratio and high post/pre kynurenine (unfavorable 
baseline and unfavorable change). There were significant differences in OS (P=0.002) (Figure 
4A) and PFS (P=0.013) (Figure 4B) for these 4 groups. Patients in Group 1 achieved extremely 
long-term OS (the median OS has not been reached after up to 57 months of median follow-up), 
but a relatively low PFS of 14 (10-17) months. Patients in Group 2 had median OS and PFS of 
25 (14-36) and 17 (0-45) months, respectively. The median OS and PFS (and their 95% CIs) 
were 36 (22-50) and 18 (0-45) months for Group 3, and 12 (8-17) and 6 (2-9) months for Group 
4, respectively. 
Pattern of failure analysis was performed for these 4 groups to study how baseline and change of 
the IDO differently impact on OS and PFS. Distant and local/regional failure were 6/13 (46%) 
and 1/13 (8%), 0/15 (0%) and 7/15 (47%), 8/19 (42%) and 2/19 (11%), 4/10 (40%) and 4/10 
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(40%) for Groups 1, 2, 3 and 4, respectively (P=0.019) (Figure 4C). Furthermore, those patients 
who developed distant progression in Group 1 had a median OS of 41 months, which was longer 
than that in group 3 and group 4 (23 and 9 months) (P=0.057) (Figure 4D).  
DISCUSSION 
This study demonstrated that 1) RT caused significant reductions in IDO activity (represented by 
K:T ratio) during-RT but IDO increased significantly post-RT (after more radiation); 2) IDO at 
baseline and post-RT correlated significantly with OS and PFS; 3) RT-induced change in 
kynurenine post-RT was significant for either OS or distant progression in an unusual manner 
(median OS did not reach, corresponded to 88 months mean OS with favorable baseline, and 0% 
distant progression under unfavorable baseline). These results support our hypotheses that RT 
can alter the IDO-mediated anti-tumor immune activity. 
This study demonstrates that IDO activity at baseline is an important prognostic marker for 
patients with NSCLC treated with fractionated RT. This is in agreement with previous studies 
that baseline IDO immune status plays a prognostic role after surgery or chemotherapy 
(16,17,20-22). Our data demonstrated low activity of IDO, i.e. low level of kynurenine or low 
K:T ratio (favorable baseline), was significantly associated with better survival. The prognostic 
significance of baseline IDO biomarkers in our patients treated with RT may serve as a strong 
validation of above studies and clinically confirms the immune suppressive role of IDO in 
NSCLC (27). Although studies with larger sample sizes are needed for RT, this has clinical 
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significance as knowing the prognosis of an individual patient may help triage the care plan of 
that patient.   
More importantly, this study is the first to demonstrate that fractionated RT in NSCLC induces 
significant change of IDO-mediated immune activity level, and such change correlates with OS, 
PFS and unusual treatment outcomes in combination with baseline IDO activity. Studies in 
animal models have shown that hypo-fractionated RT can generate synergetic immune responses 
(3,5), and there are speculations and single-case reports about activation of anti-tumor immunity 
by hypo-fractionated RT (3,4). However, there are no reports in human studies showing that RT 
can generate anti-tumor immunity in a significant number of patients. Recent results in 
KYNOTE-001 phase 1 trial suggested that previous treatment with radiotherapy in patients with 
advanced NSCLC results in longer PFS and OS with pembrolizumab treatment than that seen in 
patients who did not have previous radiotherapy (28). This findings supported that radiotherapy 
affects host immunity in NSCLC patients. Our study showed that patients with favorable RT-
induced change in combination with favorable baselines (Group 1) corresponded to extremely 
long-term OS (>60% OS up to 57 months median follow-up), suggesting RT-induced immune 
activity change may generate memory T-cells for long-term tumor control. In addition, patients 
with favorable change and unfavorable baseline (Group 2) had 0% distant progression, 
suggesting that this RT-induced anti-tumor immunity may control occult tumor cells outside the 
RT fields, a phenomenon similar to abscopal effects. However, it is unclear why patients in 
Group 1 did not have similar “abscopal” effect as in Group 2. The underlying biologic 
mechanism for this phenomenon will require further research. We speculate that relatively small 
amount of anti-tumor immune cells were activated in Group 1 patients due to their favorable 
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baseline status. They were not sufficient to control the occult diseases outside the RT fields in a 
short time, and local salvage treatment was required and able to control the distant metastasis 
developed from these occult diseases. Our data showed that the metastasis patients still had 41 
months median OS, supporting our speculation.  
Most interestingly, our data showed that RT can lead favorable or unfavorable changes of IDO 
immune activity varied with time point (dose level) or patient level. It is unclear what patient-
specific factors influence these heterogeneous RT responses. We hypothesize that both 
underdose and overdose of RT will lead to unfavorable changes of immune activity. Underdose 
will not be sufficient to generate the favorable change, while overdose will damage the immune 
system and revert into the unfavorable status. Therefore, there is an optimal RT dose for 
maximal immune activation. Because patients and tumors have heterogeneous radiosensitivities, 
the optimal RT dose could be different for different patients. We found that median K:T ratio 
and median kynurenine concentration reduced in the initial phase of RT (at 2-week, lower 
doses). This statistically significant K:T ratio reduction suggests that IDO activity may be 
suppressed by anti-tumor immunity in some patients as early as 2-week after starting RT. 
Though median kynurenine levels tended to increase, median K:T ratio remained at low levels in 
the middle phase of RT (at 4-week), while both increased at later stages (post-RT status, high 
doses). Therefore, changes of these IDO-associated molecules during-RT may serve as potential 
biomarkers to determine the optimal individualized RT dose for each patient by determining 
when to stop excessive RT. However, a slight-increase of IDO or kynurenine concentration 
during RT may not be an indication of unfavorable change, because immune response to 
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radiation damage of other normal tissues may also partially contribute to the increase. Further 
study is required to understand better the underlying mechanisms.   
Additionally, the findings from this study may be relevant to blood biomarker to guide 
multimodality clinical trials. Anti-IDO agents are available commercially and clinical trials using 
various IDO inhibitors are in progress (29). Animal studies have revealed synergies between RT 
and anti-IDO agents (30). A pilot study using an IDO inhibitor after chemotherapy in stage III-
IV NSCLC patients has generated promising results (31). A key question about combining RT 
with IDO inhibitor therapy and other immunotherapy drugs is the optimal RT dose and optimal 
time points to give IDO inhibitors. RT doses that activate anti-tumor immunity but do not cause 
excessive immune depletion are desirable.  
This study has limitations. One of them is serum sample availability. The numbers of available 
samples at different time points were diverse, which may impact study results, especially for 
inter-group comparisons. Also, the study was not powered for a subgroup analysis on 
chemotherapy-IDO activity association. Previous studies have shown synergy between 
chemotherapy and IDO inhibitors in promoting clinical responses. It is possible that potential 
synergistic effects of chemotherapy may have partially biased our results. Rather than a sole 
effect of RT, the observed phenomenon could be the combined effects of chemotherapy and 
radiotherapy.   
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Table 1 Comparison of Overall Survival and Progression Free Survival Based on Clinical Characteristics of Patients. 
Clinical factors 
Patients 
(n) 
Overall Survival  Progression Free Survival 
Death 
n (%) 
MST 
(months) 
P* HR (95% CI) 
 
 
Progressio
n n (%) 
MPT 
(months) 
P* HR (95% CI)* 
  Age (years)           
≤ 66 59 38 (64) 31 0.016 1.00 (reference)  44 (75) 16 0.235 1.00 (reference) 
> 66 51 41 (80) 14  1.03 (1.01-1.05)  42 (82) 8  1.01 (0.99-1.04) 
  Gender           
Male 81 63 (78) 22 0.040 1.00 (reference)  66 (81) 12 0.583 1.00 (reference) 
Female 29 16 (55) 41  0.56 (0.32-0.97)  20 (69) 10  0.87 (0.53-1.44) 
  Smoking           
No 7 4 (57) 43 0.402 1.00 (reference)  5 (71) 19 0.599 1.00 (reference) 
Yes 103 75 (73) 23  1.54 (0.56-4.21)  81 (79) 11  1.27 (0.52-3.15) 
  Histology           
Adenocarcinoma 33 18 (54) 31 0.061 1.00 (reference)  23 (70) 11 0.918 1.00 (reference) 
Squamous cell 38 28 (74) 16  1.83 (1.01-3.31)  29 (76) 10  1.12 (0.65-1.93) 
NOS 39 33 (85) 19  1.93 (1.08-3.42)  34 (87) 14  1.09 (0.64-1.86) 
 Tumor volume (10 
cc) 
          
≤ 16 51 35 (69) 25 0.010 1.00 (reference)  38 (74) 14 0.041 1.00 (reference) 
> 16 51 39 (76) 22  1.02 (1.00-1.03)  41 (80) 9  1.01 (1.00-1.02) 
  KPS           
≤ 80 43 36 (84) 13 < 0.001 1.00 (reference)  38 (88) 9 0.010 1.00 (reference) 
> 80 67 43 (64) 32  0.95 (0.93-0.98)  48 (72) 14  0.96 (0.94-0.99) 
  EQD2 (Gy)           
≤ 70 63 50 (79) 18 0.014 1.00 (reference)  53 (84) 8 0.004 1.00 (reference) 
> 70 47 29 (62) 32  0.97 (0.95-0.99)  33 (70) 19  0.97 (0.95-0.99) 
  Chemotherapy           
No 7 
  5 
(71) 
7 0.243 1.00 (reference)  5 (71) 5 0.476 1.00 (reference) 
Yes 103 74 (72) 23  0.58 (0.23-1.44)  81 (79) 12  0.72 (0.29-1.78) 
Abbreviations: NOS, non-otherwise specified; MST, median OS; MPT, median PFS; KPS, Karnofsky Performance Score; EQD2, the 2 Gy-per-
fraction equivalent dose; HR, hazard ratio; 95% CI, 95% confidence interval. 
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*By univariate analysis. Age, tumor volume, KPS and EQD2 were analyzed as continuous variables. 
Table 2. Association Between IDO Activity and Changes with Overall Survival and Progression Free Survival of NSCLC. 
Time points IDO activities Patients 
(n) 
Overall Survival  Progression Free Survival 
Death  
n (%) 
MST 
(months) 
P* HR (95% CI)*  
 
Progression 
n (%) 
MPT 
(months) 
P* HR (95% CI)* 
Pre-RT 
(n = 85) 
Kynurenine           
      ≤ median 43 30 (70) 22 0.887 1.00 (reference)  33 (77) 9 0.927 1.00 (reference) 
      > median 42 30 (71) 18  1.03 (0.73-1.45)  32 (76) 12  0.99 (0.71-1.37) 
  K:T ratio           
      ≤ median 43 25 (58) 36 0.011 1.00 (reference)  30 (70) 14 0.042 1.00 (reference) 
      > median 42 35 (83) 12  2.36 (1.21-4.59)  35 (83) 8  1.77 (1.02-3.05) 
Post-RT 
(n = 76) 
  Kynurenine           
      ≤ median 38 22 (58) 36 0.384 1.00 (reference)  26 (68) 15 0.235 1.00 (reference) 
      > median 38 27 (71) 25  1.07 (0.92-1.24)  29 (76) 16  1.08 (0.95-1.23) 
  K:T ratio           
      ≤ median 38 21 (55) 41 0.277 1.00 (reference)  26 (68) 25 0.739 1.00 (reference) 
      > median 38 28 (74) 24  1.44 (0.75-2.78)  29 (76) 14  1.10 (0.62-1.98) 
   
Post/Pre  
(n = 57) 
  Kynurenine           
      ≤ median 28 13 (46) 41 0.006 1.00 (reference)  16 (57) 15 0.025 1.00 (reference) 
      > median 29 22 (76) 28  1.35 (1.09-1.68)  23 (79) 14  1.31 (1.04-1.66) 
  K:T ratio           
      ≤ median 29 18 (62) 32 0.278 1.00 (reference)  19 (65) 17 0.268 1.00 (reference) 
      > median 28 17 (61) 28  1.62 (0.68-3.87)  20 (71) 11  1.57 (0.71-3.46) 
Abbreviations: MST, median OS; MPT, median PFS; HR, hazard ratio; 95% CI, 95% confidence interval. 
* From multivariate Cox proportional hazards regression models by adjusting for tumor volume, KPS, EQD2. IDO parameters were analyzed as continuous variables. 
P<0.0125 was considered statistical significance. 
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FIGURE LEGENDS 
Figure 1. Dynamic changes of IDO-associated molecular activity during and post radiotherapy. 
The top panel shows individual and mean activity levels, and the bottom panel shows spaghetti 
plots for kynurenine and K:T ratio at four time points. P-values shown were from paired t-tests. 
Error bars at figures show 95% confidence interval (CI). 
Figure 2. Baseline IDO-mediated immune activity and treatment outcomes. Pre-RT K:T ratio for 
overall survival (A); Pre-RT K:T ratio for progression free survival (B). 
Figure 3. Changes of IDO-mediated immune activity and treatment outcomes. Changes of 
kynurenine after radiotherapy (Post/pre kynurenine) associated with overall survival (A) and 
progression free survival (B). 
Figure 4. Combined effects of baseline IDO biomarkers and post-RT change with survival and 
tumor progression. Patients were stratified into 4 groups according to the medians of pre-RT K:T 
ratio (baseline immune activity) and post/pre kynurenine (change of immune activity). Group 1: 
favorable baseline and favorable change; Group 2: unfavorable baseline and favorable change; 
Group 3: favorable baseline and unfavorable change; Group 4: unfavorable baseline and change. 
(A) Comparison of overall survival (OS) in 4 groups, Group 1 showing extremely long-term OS. 
(B) Comparison of progression free survival (PFS) in 4 groups.  
(C) Comparison of tumor local/regional and distant progressions in 4 groups. The favorable 
baseline (Groups 1 and 3) corresponded to less local/regional progression, while Group 2 had 0% 
distant progression.  
(D) Comparison of OS for patients developed distant metastasis for Groups 1, 3 and 4.  












